期刊文献+

2型糖尿病糖化血红蛋白达标率及口服降糖药使用调查 被引量:3

下载PDF
导出
摘要 目的了解宁波地区口服降糖药物治疗的2型糖尿病患者糖化血红蛋白(HbA1c)达标现状,了解常用口服降糖药物使用情况。方法采用横断面调查方法,收集3家医院共1 200例2型糖尿病患者临床及实验室资料,评估HbA1c≤6.5%的达标率。结果 1200例2型糖尿病患者的平均HbA1c为(7.10±1.28)%,达标率37%。HbA1c未达标组患者年龄大,病程长,超重或者肥胖人数多,血压未达标及血脂未达标比例高。单药治疗患者占23.9%,两联55.9%,三联及以上20.2%,最常采用的单药为磺脲类(41.8%)和双胍类(21.4%)。随着用药种类的增加,HbA1c达标率由43.9%下降到20.7%。结论本地区口服降糖药物治疗的2型糖尿病患者HbA1c达标率较低,有必要进一步提高现有的糖尿病治疗和管理水平。
出处 《现代实用医学》 2011年第8期899-901,共3页 Modern Practical Medicine
  • 相关文献

参考文献8

  • 1Diabetes Control and Complications Trial Research Group. Effect of intensive dia- betes treatment on the development and progression of long term complications in adolescents with insulin dependent dia- betes mellitus : diabetes control and complications trial[J]. J Pediatr, 1994,125 (2):177-188.
  • 2Stratton I M, Adler A I, Nen H A,et al. As- sociation of glycaemia with macrovascu- lar complications of type 2 diabetes (UKPDS 35) :prospective observational study[J]. BMJ,2000,321(7258):405-412.
  • 3中华医学会糖尿病学分会.2007年中国糖尿病防治指南.中华内分泌代谢杂志,2008,24(2):2-6.
  • 4潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学(内分泌学分册),2005,25(3):174-178. 被引量:395
  • 5Pan C, Yang W, Jia W, et al. Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys[J]. Curr Med Res Opin. 2009,25 (1): 39-45.
  • 6Gaede P, Vedel P, Larsen N, et al. Multi- factorial intervention and cardiovascular disease in patients with type 2 diabetes[J]. N Engl J Med. 2003,348(5): 383-393.
  • 7袁振芳,郭晓蕙,高妍.中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析[J].中华内分泌代谢杂志,2009,25(3):282-285. 被引量:22
  • 8Yah B, Zhu D, Cheng J, et al. The status of glycemic control: a cross-sectional study of outpatients with type 2 diabetes melli- tus across primary, secondary, and tertiary hospitals in the Jiangsu province of China[J]. Clin Ther, 2010,32(5):973-983.

二级参考文献18

  • 1潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学(内分泌学分册),2005,25(3):174-178. 被引量:395
  • 2贾伟平,宁光,高鑫,严励,杨华章,李鸣,洪洁,陆志强,程桦,戚以勤,李忠文,项坤三.格列奇特缓释剂治疗2型糖尿病的多中心临床研究[J].中华医学杂志,2005,85(37):2636-2639. 被引量:19
  • 3UK Prospective Diabetes Study(UKPDS)group.Intensive blood-glucose sulphonylureas or insulin compared with conventional treatment and risk of eomplicatious in patients with type 2 diabetes(UKPDS33).Lancet,1998,352:837-853.
  • 4Stmtton IM,Adler A1,Neil HA,et al.Association of glyvaemia with macrovaseular and mierovascular complications of type 2 diabetes (UKPDS 35):prospective observational study.BMJ,2000,321:405-412.
  • 5Gaede P,Vedei P,Larsen N,et al.Multifactorial intervention and cardiovacular disease in patients with 2 diabetes,N Engl J Med,2003,348:383-393.
  • 6Guillausseau PJ.Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus:a focus on frequency of administration.Treat Endoerino1,2005,4:167 -i 75.
  • 7Guillausseau PJ.Compliance and optimisation of oral antidiabetic therapy.A longitudinal study.Presse Meal,2004,33:156-160.
  • 8Drouin P,Standl E for the diamieron MR study group.Gliclazide modified release:results of a 2-year study in patients with type 2 diabetes.Diabetes Obes Metab,2004,6:414-421.
  • 9Jacek S,Teresa KC,Wladystaw G,et al.Applieatiou of gliclazide MR in uncontrolled diabetes type 2-the treatment phase results of DINAMIC 2 study.Diabetologia Praktyezna,2003,2:133-136.
  • 10The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med,2008,358:2560-2572.

共引文献412

同被引文献10

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部